ClinicalTrials.gov
ClinicalTrials.gov Menu

Zostavax in Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01506661
Recruitment Status : Active, not recruiting
First Posted : January 10, 2012
Last Update Posted : September 18, 2017
Sponsor:
Information provided by (Responsible Party):
Oklahoma Medical Research Foundation

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Herpes Zoster (shingles) is caused by reactivation of latent varicella zoster virus (VZV) that usually occurs decades following initial exposure. The risk of developing shingles increases with age. Shingles presents as a painful, itchy blistering rash that usually involves a single portion of the skin and lasts about 7-10 days. The risk of developing shingles increases with age in healthy people, and has been shown in some studies to be increased in people with rheumatoid arthritis and other autoimmune diseases.

Zostavax, a live-attenuated vaccine against the varicella zoster virus, was first approved by the FDA for the prevention of Shingles among people 60 years and older, and is now approved for use in people aged 50 years and older. Because rheumatoid arthritis and some of the medications used to treat rheumatoid arthritis can impair the body's immune system, it is not known how much of an immune response can be generated in people with rheumatoid arthritis.

The goals of this study are to measure the immune response after standard vaccination with Zostavax in people with rheumatoid arthritis in comparison to people with healthy immune systems. All participants will be 50 years old or older, and subjects with rheumatoid arthritis will not be eligible if they are taking certain biologic medications, including TNF inhibitors (Etanercept or Adalimumab). Ten healthy subjects and 10 subjects with rheumatoid arthritis will all receive a single vaccination with Zostavax, then will be followed for 12 weeks to assess the immune response and for the development of local rash or other potential side effects.


Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Varicella Zoster Drug: Zostavax (varicella zoster virus) vaccine Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Immune Response to Varicella Zoster Vaccination (ZOSTAVAX) in Subjects With Rheumatoid Arthritis
Study Start Date : January 2012
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : October 2018

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Rheumatoid Arthritis
10 subjects with mild rheumatoid arthritis aged 50 years and older will be enrolled and will receive a single dose of Zostavax vaccine.
 Drug: Zostavax (varicella zoster virus) vaccine
Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit
Active Comparator: Healthy Subjects
10 healthy subjects aged 50 years or older who have not been previously immunized, will receive a single injection of Zostavax.
 Drug: Zostavax (varicella zoster virus) vaccine
Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. safety [ Time Frame: 12 weeks ]
    The primary outcome of the study is assessment of adverse events, including injection site reactions and development of zoster-like lesions, following vaccination in subjects with RA compared to healthy subjects


Secondary Outcome Measures :
  1. Immunogenicity [ Time Frame: 6 weeks ]
    The secondary objective of the study is immunogenicity. Specifically, the change from baseline in varicella-zoster virus-specific cell mediated immunity (assessed by IFN-g ELISpot) between subjects with RA and healthy subjects will be compared.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age ≥ 50 years
  • Willing and able to provide written informed consent
  • History of primary varicella vaccination or positive VZV IgG antibodies
  • Diagnosis of RA according to ACR criteria for > 1 year, or healthy control subject
  • Stable, mild disease activity as defined by a DAS28 score of 4.0
  • Current medical treatment for RA has been stable for 4 weeks prior to screening
  • Acceptable immunosuppressive medications are limited to Prednisone ≤ 10 mg daily Methotrexate ≤ 20 mg weekly Hydroxychloroquine ≤ 6.5 mg/kg daily Any TNF inhibitor
  • Female subjects of childbearing potential and non-sterile males must agree to use acceptable form of contraception for the duration of the study

Exclusion Criteria:

  • History of receiving any VZV-containing vaccine
  • History of herpes zoster reactivation (shingles) within 5 years of enrollment
  • Received any vaccine within 6 weeks
  • Known Hepatitis B, C or HIV virus infection
  • History of drug or alcohol abuse within 1 year
  • Rituximab therapy within 2 years of screening
  • Cyclophosphamide within 6 months of screening
  • Biologic therapy: TNF inhibitors with longer half-lives (infliximab, golimumab, etc), or other non-TNF biologic therapies (IL-1 or IL-6 inhibition, or CTLA-4Ig)
  • Use of mycophenolate mofetil within 3 months of screening
  • History of receiving immunoglobulin or other blood product within 3 months of screening
  • Allergic reaction, intolerance or other contraindication to use of famciclovir.
  • Has received an experimental/investigational agent (vaccine, drug, biologic, device, blood product, or medication) within 3 months of screening; or expects to receive another experimental/investigational agent within 6 months post immunization.
  • Pregnant or lactating women
  • Unwilling to use acceptable method of contraception for the duration of the study
  • WBC <3.0; ANC <1500; CD4+ <200
  • Proteinuria >1.5 mg/day
  • Impaired renal function defined by serum Cr >1.5
  • Transaminases > 2x upper limit of normal
  • DAS28 > 4
  • Anticipation of need to increase level of immunosuppression or add biologic therapy for 6 months following dosing.
  • History of neoplastic disease within 5 years of screening, except for completely excised non-melanoma cancer of the skin or in-situ carcinoma of the uterine cervix.
  • History of any hematological malignancy, current bleeding disorder or taking anticoagulant medication (heparin or warfarin).
  • Any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01506661


Locations
United States, Oklahoma
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
Oklahoma Medical Research Foundation
Investigators
Principal Investigator: Eliza Chakravarty, MD Oklahoma Medical Research Foundation
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Oklahoma Medical Research Foundation
ClinicalTrials.gov Identifier: NCT01506661     History of Changes
Other Study ID Numbers: OMRF11-53
First Posted: January 10, 2012    Key Record Dates
Last Update Posted: September 18, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Oklahoma Medical Research Foundation:
Rheumatoid arthritis
vaccination
immune response
varicella zoster

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Herpes Zoster
Chickenpox
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
 Autoimmune Diseases
Immune System Diseases
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs